

Apr. 1, 2024



Avkare issues voluntary nationwide recall of atovaquone oral suspension due to potential *Bacillus cereus* contamination

At Prime Therapeutics Management, we want to help you receive the best possible care. Visit **[PrimeTherapeutics.com/DrugRecalls](https://www.PrimeTherapeutics.com/DrugRecalls)** to review the latest FDA drug recalls.

About this recall:

Avkare is voluntarily recalling lot number AW0221A (expiration 08/2025) of atovaquone oral suspension, USP 750 mg/5 mL (NDC # 50268-086-12), to the consumer level due to the potential for *Bacillus cereus* contamination.

Atovaquone oral suspension is FDA-approved for prevention and treatment of a certain type of pneumonia, *Pneumocystis jiroveci* pneumonia (PCP), in adults and children 13 years of age and older who cannot take other medications, such as trimethoprim-sulfamethoxazole.

What this means to you:

In patients with a weakened immune system, the contaminated product could lead to serious, life-threatening infections, such as inflammation of the heart (endocarditis) or severe soft tissue infections.

Consumers that have product that is being recalled should stop using the product and return it to the place of purchase or discard. Consumers with questions regarding this recall can contact Avkare by phone at **855.361.3993**, Monday–Friday, 9 a.m.–5 p.m., Eastern Time (ET) or email **DrugSafety@Avkare.com**. Consumers should contact their health care provider if they have experienced any problems that may be related to taking or using this drug product.